文献速递造血干细胞移植与细胞治疗

抗T淋巴细胞球蛋白(ATLG)与抗胸腺细胞球蛋白(ATG)预防异基因造血干细胞移植后移植物抗宿主病的临床与免疫学差异比较研究

Differential Clinical and Immunological Impacts of Anti-T-Lymphocyte Globulin (ATLG) vs. Anti-Thymocyte Globulin (ATG) in Preventing Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study.
PubMed 文献 · Am J Hematol · 2025-02-04

该单中心研究纳入114例接受匹配亲缘或非亲缘供者移植的成人患者,比较ATLG(n=64)与ATG(n=50)的临床结局与免疫重建参数。ATLG组II-IV级急性GvHD发生率降低(Cox HR=0.29;95%CI 0.14-0.62,p=0.006),严重GvHD无复发生存改善(Cox HR=0.51;95%CI 0.29-0.91,p=0.027),复发率相似。ATLG组IL-15降低、IL-21升高,PD1+ T细胞显著减少,TCR免疫测序显示克隆性及多样性的定量特征相似但定性特征不同。

要点

  • ATLG较ATG使II-IV级急性GvHD风险降低(Cox HR=0.29;95%CI 0.14-0.62,p=0.006)。
  • ATLG组严重GvHD无复发生存改善(Cox HR=0.51;95%CI 0.29-0.91,p=0.027)。
  • ATLG组IL-15降低、IL-21升高,PD1+ T细胞显著减少,尤其CD8+ T细胞各分化阶段。

核心结论

  • ATLG较ATG更有效调节同种反应性T细胞活化,更好预防急性GvHD同时保留移植物抗白血病效应。
  • 这些发现促使研究者发起一项比较两种抗淋巴细胞球蛋白的多中心III期随机试验。

研究设计与样本

  • 单中心研究,纳入114例接受匹配亲缘或非亲缘供者移植的成人患者,接受ATG(n=50)或ATLG(n=64)。
  • 比较两组临床结局与广泛免疫重建参数。
  • 生物学REAL GREFFE研究在clinicaltrial.gov注册,注册号NCT03357172。

主要发现

  • ATLG较ATG使II-IV级急性GvHD发生率降低2倍(Cox HR=0.29;95%CI 0.14-0.62,p=0.006)。
  • 两组复发发生率相似。
  • ATLG组严重GvHD无复发生存改善(Cox HR=0.51;95%CI 0.29-0.91,p=0.027)。
  • ATLG组IL-15血清浓度降低、IL-21血清浓度升高,PD1+ T细胞显著减少,主要见于CD8+ T细胞各分化阶段。
  • TCR vβ免疫测序显示两组克隆性和多样性定量特征相似,但ATLG组超扩增T细胞克隆减少、CDR3长度分布变异性更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Both anti-T-lymphocyte globulin (ATLG-Grafalon) and anti-thymocyte globulin (ATG-Thymoglobulin) prevent acute and chronic graft-versus-host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Despite distinct manufacturing and biological characteristics, the two brands of rabbit anti-lymphocyte globulins have never been compared in a prospective way. In this monocentric study, 114 adult patients transplanted with a matched related or unrelated donor after receiving either ATG (n = 50) or ATLG (n = 64) were included to compare their clinical outcomes and broad immune reconstitution parameters. The use of ATLG, compared with ATG, was associated with a 2-fold reduction in Grade II-IV acute GvHD incidence (Cox HR = 0.29; 95% CI 0.14-0.62, p = 0.006), similar relapse incidence, and improved severe GvHD and relapse-free survival (GRFS) (Cox HR = 0.51; 95% CI 0.29-0.91, p = 0.027). Biologically, reduced IL-15 but increased IL-21 serum concentrations and a significant reduction of PD1+ T cells, mainly across all differentiated stages of CD8+ T cells, were observed in the ATLG group. Immunosequencing of vβ T cell receptor (TCR) repertoires showed similar quantitative characteristics in terms of clonality and diversity across the two groups but different qualitative features, with reduced hyper-expanded T cell clones and higher variability in the distribution of complementarity-determining region 3 (CDR3) lengths in the ATLG group. Altogether, these results suggest that ATLG more effectively regulates alloreactive T cell activation, leading to better prevention of acute GvHD while preserving the graft-versus-leukemia response. These findings led us to initiate a multicentric Phase III randomized trial comparing the two anti-lymphocyte globulins. Trial Registration: The biological REAL GREFFE study was registered in clinicaltrial.gov under the number: NCT03357172.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Notarantonio AB, Morisset S, Piucco R, et al. Differential Clinical and Immunological Impacts of Anti-T-Lymphocyte Globulin (ATLG) vs. Anti-Thymocyte Globulin (ATG) in Preventing Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study. Am J Hematol. 2025. PMID: 39905816. doi:10.1002/ajh.27619

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。